RE:RE:RE:Stock Market Shifts into Small Caps And ONCY shifting gears into a US based global financial institution with world-class specialized talent, throws open the doors to the Accelerated Approval pathway for ONCY's pelareorep in combination with paclitaxel for the treatment of HR+/HER2- metastatic Breast Cancer used in 2 different scenarios- (1) either prior to (in ADC intolerant) which was originally planned before ADC therapy, or (2) following ADC therapy (in ADC failure)., at a time when the markets are shifting into small cap stocks and Big Pharma is ramping up M&A.